Greenwich LifeSciences (GLSI) Research & Development (2019 - 2026)
Greenwich LifeSciences' (GLSI) quarterly Research & Development came in at $8.3 million in Q4 2025, down 4.84% YoY from $8.7 million in Q4 2024, and up 152.99% on a QoQ basis from $3.3 million in Q3 2025.
Greenwich LifeSciences (GLSI) Research & Development (2019 - 2026) Analysis & Trends
Greenwich LifeSciences (GLSI) has 7 years of Research & Development data on file, last reported at $8.3 million in Q4 2025.
- Quarterly Research & Development fell 4.84% year-over-year to $8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.2 million (up 11.24% YoY) and the FY2025 annual result came in at $17.2 million, up 11.24% from the prior year.
- Research & Development rose to $8.3 million in Q4 2025, from $3.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.7 million in Q4 2024 to a low of $281977.0 in Q1 2021.
- A 5-year average of $2.5 million and a median of $2.2 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 488.99% — and 2023, when it fell 5.09%.
- Tracing GLSI's Research & Development over 5 years: stood at $2.1 million in 2021, then advanced by 19.1% to $2.5 million in 2022, then retreated by 5.09% to $2.3 million in 2023, then jumped by 272.3% to $8.7 million in 2024, then declined by 4.84% to $8.3 million in 2025.
- The last three Research & Development figures came in at $8.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Greenwich LifeSciences | 246.39 Mn | 246.39 Mn | - | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 8.27 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 3.42 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 8.69 Mn |
| Sep 30, 2024 | 2.29 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 2.19 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 1.38 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 2.46 Mn |
| Sep 30, 2022 | 1.72 Mn |
| Jun 30, 2022 | 633,250.00 |
| Mar 31, 2022 | 1.66 Mn |
| Dec 31, 2021 | 2.06 Mn |
| Sep 30, 2021 | 657,096.00 |
| Jun 30, 2021 | 556,534.00 |